SCOUT-HCM 56-Week Data Reinforce Mavacamten Durability in Teens

In an interview with Pharmacy Times, Joseph Rossano, MD, MS, FAAP, FACC, chief of cardiology at Children’s Hospital of Philadelphia, discussed 56-week results from the phase 3 SCOUT-HCM trial of mavacamten (Camzyos; Bristol Myers Squibb) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Rossano said the investigators were pleased with the longer-term data, which showed that the effects observed with mavacamten at 28 weeks were sustained at 56 weeks. Patients who received mavacamten throughout the study maintained a substantial reduction in the left ventricular outflow tract (LVOT) gradient.

Rossano also highlighted the patients who switched from placebo to mavacamten at week 28. Their reductions in LVOT gradients, as well as their overall outcomes and other exploratory end points, mirrored those of the patients who were randomly assigned to mavacamten at the start of the trial. According to Rossano, this replication in an additional cohort offers reassurance that the results from the initial 28-week period were not a fluke.

From a safety standpoint, Rossano said there were no surprises: mavacamten was well tolerated, and there were no real safety concerns. For pharmacists, the findings add confidence that the early benefit of mavacamten persisted with continued therapy and that a comparable response was seen in patients who began treatment later.